Cullinan Therapeutics (CGEM) · CLN-978
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: Q4 2026
• OUTRACE SjD o In Q4 2026, the Company plans to share initial data from the single target dose escalation portion of the study.
EX-99.1 · filed · SEC filing
After
Stated timing: December
The Company plans to share both multi-dose and single target dose regimen data from each of its ongoing Phase 1 clinical trials of CLN-978 in patients with (i) treatment-refractory moderate to severe systemic lupus erythematosus ("SLE"), (ii) difficult-to-treat rheumatoid arthritis ("RA") and (iii) treatment-refractory moderate to severe Sjögren's disease in December.
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/CGEM-cln-978-2026-09-24, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/CGEM-cln-978-2026-09-24
Cullinan Therapeutics (CGEM) pipeline and stated timing · Calendar · Companies A–Z